99mTc‐labeled oligomeric nanoparticles as potential agents for folate receptor‐positive tumor targeting. (22nd February 2018)

• Record Type: Journal Article
• Authors: Liang, Lili; Zhang, Xueqian; Su, Xiaoyu; Li, Jianchun; Tian, Yong; Xue, Hongbao; Xu, Huiqin
• Is Part Of: Journal of labelled compounds & radiopharmaceuticals. Volume 61:Number 2(2018)
• Page Start: 54
• Page End: 60
• Publication Date: 2018-02-22
• Subjects: folic acid -- nanomaterial -- radiolabeling -- technetium (99m); Tracers (Chemistry) -- Periodicals; Radiopharmaceuticals -- Periodicals; 615.8424
• DOI: 10.1002/jlcr.3577
• Languages: English
• ISSNs: 0362-4803

Abstract

Abstract : One type of biocompatible nanoparticles functionalized with folate and 99m Tc was successfully synthesized. Maleimide‐folic acid (Mal‐FA) was selected to covalently conjugate with ‐SH of the nanoparticles (NPs ) to prepareNPs‐FA for targeting. 99m Tc was selected to conjugate with ‐NH2 and ‐SH groups of cysteine residues on the surface of NPs to prepareNPs‐FA‐ 99m Tc for radioactive counting. The ability to target folate receptors ofNPs‐FA‐ 99m Tc was assessed in uptake studies with folate‐receptor–positive human HepG2 cells. The results showed that the as‐prepared NPs can selectively uptake by folate receptor‐overexpressing HepG2 tumor cells in vitro. The oligomeric hybrid NPs radiolabeled with 99m Tc may develop to be SPECT/CT imaging biomaterials with high selectivity. Abstract : One type of biocompatible, oligomeric nanoparticles NPs‐FA‐ 99m Tc was successfully synthesized. The nanoparticle was functionalized with folate (FA) for targeting and 99m Tc for radioactive count and imaging. The as‐prepared nanoparticles showed high targeting ability over folate‐receptor‐positive HepG2 tumor cells. The oligomeric hybrid nanoparticles might develop to be SPECT/CT imaging biomaterials with high selectivity.